1-(3-Ethyl-6-methylsulfanylindazol-1-yl)propan-2-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 1-(3-Ethyl-6-methylsulfanylindazol-1-yl)propan-2-amine
• 化学式: C₁₃H₁₉N₃S
• 分子量: 249.38
• InChiKey: AZGLXCKHALIYEZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  69.1
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Treatment of incontinence
  申请人：Pfizer Inc

  公开号：US20040235856A1

  公开（公告）日：2004-11-25

  The present invention relates to the use of agonists of 5-HT2C receptors for the treatment of urinary incontinence, preferably mixed incontinence or stress urinary incontinence. The invention also relates to the use of antagonists of 5-HT2C receptors for the treatment of urine retention. The present invention also relates to a method of treatment of incontinence, to assays to screen for compounds useful in the treatment of incontinence, and to methods of preparing compositions for the treatment of urinary incontinence.

  本发明涉及使用 5-HT2C 受体的激动剂治疗尿失禁，最好是混合性尿失禁或压力性尿失禁。本发明还涉及使用 5-HT2C 受体拮抗剂治疗尿潴留。本发明还涉及一种治疗尿失禁的方法，涉及筛选治疗尿失禁有用化合物的检测方法，以及制备治疗尿失禁组合物的方法。
• INDAZOLE DERIVATIVES WITH 5-HT2 RECEPTOR ACTIVITY
  申请人：VERNALIS RESEARCH LIMITED

  公开号：EP1129078B1

  公开（公告）日：2006-03-15
• Treatment of Incontinence
  申请人：McMurray Gordon

  公开号：US20080146583A1

  公开（公告）日：2008-06-19

  The present invention relates to the use of agonists of 5-HT2C receptors for the treatment of urinary incontinence, preferably mixed incontinence or stress urinary incontinence. The invention also relates to the use of antagonists of 5-HT2C receptors for the treatment of urine retention. The present invention also relates to a method of treatment of incontinence, to assays to screen for compounds useful in the treatment of incontinence, and to methods of preparing compositions for the treatment of urinary incontinence.
• Treatment Of Incontinence
  申请人：McMurray Gordon

  公开号：US20110152272A1

  公开（公告）日：2011-06-23

  The present invention relates to the use of agonists of 5-HT2C receptors for the treatment of urinary incontinence, preferably mixed incontinence or stress urinary incontinence. The invention also relates to the use of antagonists of 5-HT2C receptors for the treatment of urine retention. The present invention also relates to a method of treatment of incontinence, to assays to screen for compounds useful in the treatment of incontinence, and to methods of preparing compositions for the treatment of urinary incontinence.
• US6552062B1
  申请人：——

  公开号：US6552062B1

  公开（公告）日：2003-04-22